{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T00:54:42Z","timestamp":1793840082485,"version":"4.6.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["[201488\/Z\/16\/Z]"],"award-info":[{"award-number":["[201488\/Z\/16\/Z]"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Balliol Jowett Society"},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["C64881\/A26189"],"award-info":[{"award-number":["C64881\/A26189"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["C2195\/A19716"],"award-info":[{"award-number":["C2195\/A19716"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["[201488\/Z\/16\/Z]"],"award-info":[{"award-number":["[201488\/Z\/16\/Z]"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["[201488\/Z\/16\/Z]"],"award-info":[{"award-number":["[201488\/Z\/16\/Z]"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["WT109965MA"],"award-info":[{"award-number":["WT109965MA"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013373","name":"NIHR Oxford Biomedical Research Centre","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100013373","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1038\/s41591-019-0734-6","type":"journal-article","created":{"date-parts":[[2020,2,10]],"date-time":"2020-02-10T12:04:02Z","timestamp":1581336242000},"page":"193-199","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":351,"title":["Peripheral CD8+ T cell characteristics associated with durable responses to immune checkpoint blockade in patients with metastatic melanoma"],"prefix":"10.1038","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7413-5002","authenticated-orcid":false,"given":"Benjamin P.","family":"Fairfax","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chelsea A.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Watson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isar","family":"Nassiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Danielli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3961-8572","authenticated-orcid":false,"given":"Hai","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elise A.","family":"Mah\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosalin","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7656-728X","authenticated-orcid":false,"given":"Victoria","family":"Woodcock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoe","family":"Traill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2312-3754","authenticated-orcid":false,"given":"M. Hussein","family":"Al-Mossawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0377-5536","authenticated-orcid":false,"given":"Julian C.","family":"Knight","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Klenerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miranda","family":"Payne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0167-1685","authenticated-orcid":false,"given":"Mark R.","family":"Middleton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,2,10]]},"reference":[{"key":"734_CR1","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/nature13954","volume":"515","author":"PC Tumeh","year":"2014","unstructured":"Tumeh, P. C. et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515, 568\u2013571 (2014).","journal-title":"Nature"},{"key":"734_CR2","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1126\/science.aao1710","volume":"359","author":"D Pan","year":"2018","unstructured":"Pan, D. et al. A major chromatin regulator determines resistance of tumor cells to T cell-mediated killing. Science 359, 770\u2013775 (2018).","journal-title":"Science"},{"key":"734_CR3","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1038\/s41588-018-0200-2","volume":"50","author":"D Miao","year":"2018","unstructured":"Miao, D. et al. Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors. Nat. Genet. 50, 1271\u20131281 (2018).","journal-title":"Nat. Genet."},{"key":"734_CR4","doi-asserted-by":"publisher","first-page":"eaaf8399","DOI":"10.1126\/science.aaf8399","volume":"355","author":"T Davoli","year":"2017","unstructured":"Davoli, T., Uno, H., Wooten, E. C. & Elledge, S. J. Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy. Science 355, eaaf8399 (2017).","journal-title":"Science"},{"key":"734_CR5","doi-asserted-by":"publisher","first-page":"4102","DOI":"10.1200\/JCO.2016.67.2477","volume":"34","author":"AI Daud","year":"2016","unstructured":"Daud, A. I. et al. Programmed death-ligand\u20091 expression and response to the anti\u2013programmed death\u20091 antibody pembrolizumab in melanoma. J. Clin. Oncol. 34, 4102\u20134109 (2016).","journal-title":"J. Clin. Oncol."},{"key":"734_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-05047-1","volume":"9","author":"L Brochez","year":"2018","unstructured":"Brochez, L. et al. Challenging PD-L1 expressing cytotoxic T cells as a predictor for response to immunotherapy in melanoma. Nat. Commun. 9, 2921 (2018).","journal-title":"Nat. Commun."},{"key":"734_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-00608-2","volume":"8","author":"N Jacquelot","year":"2017","unstructured":"Jacquelot, N. et al. Predictors of responses to immune checkpoint blockade in advanced melanoma. Nat. Commun. 8, 592 (2017).","journal-title":"Nat. Commun."},{"issue":"11","key":"734_CR8","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1038\/s41591-018-0094-7","volume":"24","author":"Carsten Krieg","year":"2018","unstructured":"Krieg, C. et al. Author correction: high-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy. Nat. Med. 24, 1773\u20131775 (2018).","journal-title":"Nature Medicine"},{"key":"734_CR9","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/S1470-2045(18)30078-0","volume":"19","author":"JL McQuade","year":"2018","unstructured":"McQuade, J. L. et al. Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis. Lancet Oncol. 19, 310\u2013322 (2018).","journal-title":"Lancet Oncol."},{"key":"734_CR10","doi-asserted-by":"publisher","first-page":"5347","DOI":"10.1158\/1078-0432.CCR-18-1116","volume":"24","author":"CH Kugel","year":"2018","unstructured":"Kugel, C. H. et al. Age correlates with response to anti-PD1, reflecting age-related differences in intratumoral effector and regulatory T-cell populations. Clin. Cancer Res. 24, 5347\u20135356 (2018).","journal-title":"Clin. Cancer Res."},{"key":"734_CR11","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1126\/science.aaf2834","volume":"352","author":"CU Blank","year":"2016","unstructured":"Blank, C. U., Haanen, J. B., Ribas, A. & Schumacher, T. N. The \u2018cancer immunogram\u2019. Science 352, 658\u2013660 (2016).","journal-title":"Science"},{"key":"734_CR12","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/nature22079","volume":"545","author":"AC Huang","year":"2017","unstructured":"Huang, A. C. et al. T-cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature 545, 60\u201365 (2017).","journal-title":"Nature"},{"key":"734_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-10-146","volume":"10","author":"W Wang","year":"2012","unstructured":"Wang, W. et al. Biomarkers on melanoma patient T cells associated with ipilimumab treatment. J. Transl. Med. 10, 146 (2012).","journal-title":"J. Transl. Med."},{"key":"734_CR14","doi-asserted-by":"publisher","first-page":"950","DOI":"10.4049\/jimmunol.1401686","volume":"194","author":"R Das","year":"2015","unstructured":"Das, R. et al. Combination therapy with anti\u2013CTLA-4 and Anti\u2013PD-1 leads to distinct immunologic changes in vivo. J. Immunol. 194, 950\u2013959 (2015).","journal-title":"J. Immunol."},{"key":"734_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-9-559","volume":"9","author":"P Langfelder","year":"2008","unstructured":"Langfelder, P. & Horvath, S. WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics 9, 559 (2008).","journal-title":"BMC Bioinformatics"},{"key":"734_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s12859-018-2053-1","volume":"19","author":"PST Russo","year":"2018","unstructured":"Russo, P. S. T. et al. CEMiTool: a Bioconductor package for performing comprehensive modular co-expression analyses. BMC Bioinformatics 19, 56 (2018).","journal-title":"BMC Bioinformatics"},{"key":"734_CR17","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1038\/nmeth.3364","volume":"12","author":"DA Bolotin","year":"2015","unstructured":"Bolotin, D. A. et al. MiXCR: software for comprehensive adaptive immunity profiling. Nat. Methods 12, 380\u2013381 (2015).","journal-title":"Nat. Methods"},{"key":"734_CR18","doi-asserted-by":"crossref","unstructured":"Bates, D., M\u00e4chler, M., Bolker, B. & Walker, S. Fitting linear mixed-effects models using lme4. Preprint at https:\/\/arxiv.org\/abs\/1406.5823 (2014).","DOI":"10.18637\/jss.v067.i01"},{"key":"734_CR19","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1038\/s41590-018-0049-7","volume":"19","author":"The Milieu Int\u00e9rieur Consortium","year":"2018","unstructured":"The Milieu Int\u00e9rieur Consortiumet al. Natural variation in the parameters of innate immune cells is preferentially driven by genetic factors. Nat. Immunol. 19, 302\u2013314 (2018).","journal-title":"Nat. Immunol."},{"key":"734_CR20","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1128\/JVI.73.3.2099-2108.1999","volume":"73","author":"MP Weekes","year":"1999","unstructured":"Weekes, M. P., Wills, M. R., Mynard, K., Carmichael, A. J. & Sissons, J. G. The memory cytotoxic T-lymphocyte (CTL) response to human cytomegalovirus infection contains individual peptide-specific CTL clones that have undergone extensive expansion in vivo. J. Virol. 73, 2099\u20132108 (1999).","journal-title":"J. Virol."},{"key":"734_CR21","doi-asserted-by":"publisher","first-page":"8140","DOI":"10.1128\/JVI.74.17.8140-8150.2000","volume":"74","author":"GMA Gillespie","year":"2000","unstructured":"Gillespie, G. M. A. et al. Functional heterogeneity and high frequencies of cytomegalovirus-specific CD8+ T lymphocytes in healthy seropositive donors. J. Virol. 74, 8140\u20138150 (2000).","journal-title":"J. Virol."},{"key":"734_CR22","doi-asserted-by":"publisher","first-page":"3835","DOI":"10.1182\/blood-2015-03-631853","volume":"125","author":"Y Suessmuth","year":"2015","unstructured":"Suessmuth, Y. et al. CMV reactivation drives posttransplant T-cell reconstitution and results in defects in the underlying TCR-\u03b2 repertoire. Blood 125, 3835\u20133850 (2015).","journal-title":"Blood"},{"key":"734_CR23","first-page":"128ra42","volume":"4","author":"GC Wang","year":"2012","unstructured":"Wang, G. C., Dash, P., McCullers, J. A., Doherty, P. C. & Thomas, P. G. T. Cell receptor diversity inversely correlates with pathogen-specific antibody levels in human cytomegalovirus infection. Sci. Transl. Med. 4, 128ra42 (2012).","journal-title":"Sci. Transl. Med."},{"key":"734_CR24","doi-asserted-by":"publisher","first-page":"6526","DOI":"10.1128\/JVI.00169-13","volume":"87","author":"B Durovic","year":"2013","unstructured":"Durovic, B. et al. Epstein\u2013Barr virus negativity among individuals older than 60 years is associated with HLA-C and HLA-Bw4 variants and tonsillectomy. J. Virol. 87, 6526\u20136529 (2013).","journal-title":"J. Virol."},{"key":"734_CR25","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1038\/s41586-018-0130-2","volume":"557","author":"Y Simoni","year":"2018","unstructured":"Simoni, Y. et al. Bystander CD8+ T cells are abundant and phenotypically distinct in human tumour infiltrates. Nature 557, 575\u2013579 (2018).","journal-title":"Nature"},{"key":"734_CR26","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1016\/j.cell.2017.05.035","volume":"169","author":"C Zheng","year":"2017","unstructured":"Zheng, C. et al. Landscape of infiltrating T cells in liver cancer revealed by single-cell sequencing. Cell 169, 1342\u20131356.e16 (2017).","journal-title":"Cell"},{"key":"734_CR27","doi-asserted-by":"publisher","unstructured":"Nicolet, B. P. et al. CD29 marks superior cytotoxic human T cells. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/562512 (2019).","DOI":"10.1101\/562512"},{"key":"734_CR28","doi-asserted-by":"publisher","first-page":"eaah3560","DOI":"10.1126\/scitranslmed.aah3560","volume":"9","author":"W Roh","year":"2017","unstructured":"Roh, W. et al. Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. Sci. Transl. Med. 9, eaah3560 (2017).","journal-title":"Sci. Transl. Med."},{"key":"734_CR29","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/nmeth.3317","volume":"12","author":"D Kim","year":"2015","unstructured":"Kim, D., Langmead, B. & Salzberg, S. L. HISAT: a fast spliced aligner with low memory requirements. Nat. Methods 12, 357\u2013360 (2015).","journal-title":"Nat. Methods"},{"key":"734_CR30","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1093\/bioinformatics\/btu638","volume":"31","author":"S Anders","year":"2015","unstructured":"Anders, S., Pyl, P. T. & Huber, W. HTSeq\u2014a Python framework to work with high-throughput sequencing data. Bioinformatics 31, 166\u2013169 (2015).","journal-title":"Bioinformatics"},{"key":"734_CR31","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1093\/bioinformatics\/btp352","volume":"25","author":"H Li","year":"2009","unstructured":"Li, H. et al. The sequence alignment\/Map format and SAMtools. Bioinformatics 25, 2078\u20132079 (2009).","journal-title":"Bioinformatics"},{"key":"734_CR32","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.ajhg.2012.09.004","volume":"91","author":"G Jun","year":"2012","unstructured":"Jun, G. et al. Detecting and estimating contamination of human dna samples in sequencing and array-based genotype data. Am. J. Hum. Genet. 91, 839\u2013848 (2012).","journal-title":"Am. J. Hum. Genet."},{"key":"734_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).","journal-title":"Genome Biol."},{"key":"734_CR34","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1111\/j.1654-1103.2003.tb02228.x","volume":"14","author":"P Dixon","year":"2003","unstructured":"Dixon, P. VEGAN, a package of R functions for community ecology. J. Veg. Sci. 14, 927\u2013930 (2003).","journal-title":"J. Veg. Sci."},{"key":"734_CR35","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-016-0384-y","volume":"8","author":"H Fang","year":"2016","unstructured":"Fang, H., Knezevic, B., Burnham, K. L. & Knight, J. C. XGR software for enhanced interpretation of genomic summary data, illustrated by application to immunological traits. Genome Med. 8, 129 (2016).","journal-title":"Genome Med."},{"key":"734_CR36","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1038\/s41588-019-0456-1","volume":"51","author":"The ULTRA-DD Consortium","year":"2019","unstructured":"The ULTRA-DD Consortiumet al. A genetics-led approach defines the drug target landscape of 30 immune-related traits. Nat. Genet. 51, 1082\u20131091 (2019).","journal-title":"Nat. Genet."},{"key":"734_CR37","doi-asserted-by":"crossref","unstructured":"McCarthy, D. J., Campbell, K. R., Lun, A. T. L. & Wills, Q. F. Scater: pre-processing, quality control, normalization and visualization of single-cell RNA-seq data in R. Bioinformatics 8, 1179\u20131186 (2017).","DOI":"10.1093\/bioinformatics\/btw777"},{"key":"734_CR38","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-016-0947-7","volume":"17","author":"AT Lun","year":"2016","unstructured":"Lun, A. T., Bach, K. & Marioni, J. C. Pooling across cells to normalize single-cell RNA sequencing data with many zero counts. Genome Biol. 17, 75 (2016).","journal-title":"Genome Biol."},{"key":"734_CR39","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/nmeth.3252","volume":"12","author":"W Huber","year":"2015","unstructured":"Huber, W. et al. Orchestrating high-throughput genomic analysis with Bioconductor. Nat. Methods 12, 115\u2013121 (2015).","journal-title":"Nat. Methods"},{"key":"734_CR40","first-page":"2122","volume":"5","author":"ATL Lun","year":"2016","unstructured":"Lun, A. T. L., McCarthy, D. J. & Marioni, J. C. A step-by-step workflow for low-level analysis of single-cell RNA-seq data with Bioconductor. F1000Res. 5, 2122 (2016).","journal-title":"F1000Res."},{"key":"734_CR41","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1182\/blood-2017-12-821413","volume":"131","author":"JS Dahlin","year":"2018","unstructured":"Dahlin, J. S. et al. A single-cell hematopoietic landscape resolves 8 lineage trajectories and defects in Kit mutant mice. Blood 131, e1\u2013e11 (2018).","journal-title":"Blood"},{"key":"734_CR42","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1016\/j.cell.2019.05.031","volume":"177","author":"T Stuart","year":"2019","unstructured":"Stuart, T. et al. Comprehensive integration of single-cell data. Cell 177, 1888\u20131902.e21 (2019).","journal-title":"Cell"}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41591-019-0734-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41591-019-0734-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41591-019-0734-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T18:01:03Z","timestamp":1684605663000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-019-0734-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":42,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["734"],"URL":"https:\/\/doi.org\/10.1038\/s41591-019-0734-6","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.737350169.793574043","asserted-by":"object"}]},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"29 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.H.M. reports personal fees from Amgen, grants and personal fees from Roche, grants from Astrazeneca, grants and personal fees from GSK, personal fees and other from Novartis, other from Millenium, personal fees, non-financial support and other from Immunocore, personal fees and other from BMS, personal fees and other from Eisai, other from Pfizer, personal fees, non-financial support and other from Merck\/MSD, personal fees and other from Rigontec (acquired by MSD), other from Regeneron, personal fees from BiolineRx, personal fees and other from Array Biopharma (now Pfizer), non-financial support and other from Replimune, outside the submitted work. M.P. has received support with conference travel, and fees for advisory work and speaking from Amgen, BMS, L'Oreal, MSD, Novartis and Pierre Fabre. B.P.F. received support with conference travel from BMS.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}